- Home
- PHK vs AKBA Comparison
PHK vs AKBA Comparison
Compare PHK & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHK
- AKBA
- Stock Information
- Founded
- PHK 2003
- AKBA 2007
- Country
- PHK United States
- AKBA United States
- Employees
- PHK N/A
- AKBA N/A
- Industry
- PHK Finance/Investors Services
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- PHK Finance
- AKBA Health Care
- Exchange
- PHK Nasdaq
- AKBA Nasdaq
- Market Cap
- PHK 842.0M
- AKBA 729.1M
- IPO Year
- PHK N/A
- AKBA 2014
- Fundamental
- Price
- PHK $4.86
- AKBA $2.92
- Analyst Decision
- PHK
- AKBA Strong Buy
- Analyst Count
- PHK 0
- AKBA 5
- Target Price
- PHK N/A
- AKBA $6.90
- AVG Volume (30 Days)
- PHK 491.5K
- AKBA 2.5M
- Earning Date
- PHK 01-01-0001
- AKBA 11-06-2025
- Dividend Yield
- PHK 12.61%
- AKBA N/A
- EPS Growth
- PHK N/A
- AKBA N/A
- EPS
- PHK N/A
- AKBA N/A
- Revenue
- PHK N/A
- AKBA $203,733,000.00
- Revenue This Year
- PHK N/A
- AKBA $43.91
- Revenue Next Year
- PHK N/A
- AKBA $32.09
- P/E Ratio
- PHK N/A
- AKBA N/A
- Revenue Growth
- PHK N/A
- AKBA 16.75
- 52 Week Low
- PHK $4.13
- AKBA $1.30
- 52 Week High
- PHK $5.15
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- PHK 34.04
- AKBA 51.87
- Support Level
- PHK $4.86
- AKBA $2.69
- Resistance Level
- PHK $4.99
- AKBA $3.10
- Average True Range (ATR)
- PHK 0.04
- AKBA 0.14
- MACD
- PHK -0.02
- AKBA 0.03
- Stochastic Oscillator
- PHK 38.35
- AKBA 59.09
About PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. Its secondary objective is to seek capital appreciation.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.